For women with dense breast tissue, a mammogram can be an imperfect screen. Dense tissue can hide cancers, and it also raises the risk of developing breast cancer, so many women are offered supplemental ultrasound after a normal mammogram. But until recently, it wasn’t entirely clear whether the two main ultrasound approaches—automated breast ultrasound, or ABUS, and the more traditional handheld ultrasound, or HHUS—perform differently in the real world. A large observational study published in the Journal of the American College of Radiology set out to compare them directly, and the results offer meaningful reassurance for patients and nurses alike. The study looked at a range of outcomes: abnormal interpretation, also called recall rate; how often women were told to return for a short-interval follow-up, which corresponds to a final BI-RADS 3 assessment; biopsy recommendation rate; cancer detection rate; false-positive rates; and positive predictive values. To make the comparison fair, the researchers adjusted for a number of factors that could influence results, including each woman’s Breast Cancer Surveillance Consortium 5-year invasive breast cancer risk, the type of facility and whether it was for-profit, how much time had passed since the woman’s last mammogram, and whether it was a first or subsequent screening round. The two groups of women were broadly similar in age and breast density, although ABUS was more often used in non-Hispanic White women, in later study years, and in office settings rather than hospitals. That matters because it means the comparison wasn’t a randomized trial, but it still gives a useful picture of how these technologies perform in everyday practice.
The big question many women and nurses will want answered is whether ABUS reduces false-positive results compared with handheld ultrasound. In this study, the answer appears to be yes, at least in terms of initial callbacks and short-interval follow-up recommendations. After adjustment, ABUS was associated with a lower abnormal interpretation rate—14.9 percent, compared with 19.2 percent for HHUS. It was also associated with a much lower short-interval follow-up recommendation rate: only 3.0 percent for ABUS, versus 14.6 percent for HHUS. And the false-positive initial assessment rate was 14.6 percent with ABUS, compared with 19.1 percent with HHUS. These numbers translate into absolute differences of roughly 4 percentage points for abnormal interpretations, nearly 12 percentage points for short-interval follow-up, and 4.5 percentage points for false-positive initial assessments. In other words, for every 100 women screened, ABUS meant about 12 fewer women were told to come back in six months for another look. That is not a small difference when you consider the anxiety and logistical burden that comes with a follow-up appointment. The pattern held even when the researchers looked only at five facilities that used both modalities. At those sites, abnormal interpretation rates were 16.9 percent for ABUS and 17.6 percent for HHUS, and short-interval follow-up rates were 35.2 versus 131.6 per 1,000 examinations. That is a dramatic difference in how often women were placed into a “wait and watch” category, and it suggests that ABUS may help reduce the emotional and practical toll of repeated imaging.
Of course, reducing false positives would mean little if ABUS also missed cancers or led to fewer biopsies. Here, the study found no statistically significant difference between the two modalities. The unadjusted screen detection rate was 2.6 per 1,000 examinations with ABUS versus 1.7 per 1,000 with HHUS, a difference that could have been due to chance. The positive predictive value of biopsy—meaning the percentage of biopsies that actually found cancer—was 10.0 percent for ABUS versus 6.3 percent for HHUS. That looks like about a 50 percent improvement, but again, it was not statistically significant. Adjusted biopsy recommendation rates were nearly identical: 3.0 percent for ABUS and 2.9 percent for HHUS. Adjusted false-positive biopsy recommendation rates were also the same, at 2.7 percent for both modalities. In total, 35 cancers were detected by HHUS and 11 by ABUS. The proportion of detected cancers that were in situ—meaning contained within the milk ducts and not yet invasive—was 26 percent with HHUS versus 9 percent with ABUS, but that difference was not statistically significant either. What this means for patients is reassuring: both approaches found cancers, and both led to similar biopsy rates. But ABUS did so while generating fewer short-interval follow-up recommendations, which suggests that women who undergo ABUS may be spared some extra scans and waiting without any apparent reduction in cancer detection. It is important not to overstate this, because the study was observational and did not directly measure sensitivity, but the overall pattern is encouraging.
Why did the two modalities produce such different recall patterns? The type of initial recall differed. ABUS was associated with a higher rate of initial BI-RADS 0 assessments—15 percent, compared with 8 percent for HHUS—while HHUS produced far more BI-RADS 3 assessments at initial interpretation, 10 percent versus just 1 percent for ABUS. That distinction is clinically important. A BI-RADS 0 result means “incomplete—need additional imaging evaluation.” It is not a cancer diagnosis, but it does require the woman to return for more imaging. A BI-RADS 3 result means “probably benign—short-interval follow-up suggested,” which also involves another appointment, but usually at six months rather than immediately. The researchers explained that this difference is exactly what you would expect from how the two technologies work. With ABUS, the images are interpreted after the patient has already left the facility, so if there is any question, the radiologist cannot simply ask the sonographer to take another look. Instead, the finding is marked as BI-RADS 0 and the woman is asked to come back for a diagnostic handheld ultrasound to resolve it. With HHUS, a sonographer or radiologist is present in real time and can obtain additional focused images on the spot, allowing them to make a final assessment more often. The authors also speculated that many ABUS recalls may be related to imaging artifacts—things like shadows or reflections that look suspicious but disappear during diagnostic workup, allowing a negative or benign final assessment. They added that reader training and experience likely play an important role in ABUS accuracy, whereas operator dependence and image quality variation have a greater effect on HHUS. For patients, this means a BI-RADS 0 result after ABUS is often just a step in the process, not a sign that something is seriously wrong.
For oncology nurses, these findings have practical implications that go beyond the statistics. The first is to prepare patients for what a recall actually means. Under ABUS, patients may be more likely to receive an initial BI-RADS 0 result requesting additional imaging. That can be terrifying if the patient does not understand that it simply indicates an incomplete assessment, not a cancer diagnosis. The study authors referenced a recent Oncology Nursing News blog by Emily Mason Beard, BSN, RN, OCN, CBCN, who described exactly this problem: a patient received a BI-RADS 0 report without clinical context and immediately feared she had cancer. The nurse’s timely explanation made all the difference. Nurses can play that same role by explaining before the screening that a BI-RADS 0 is a “please come back for more pictures” result, not a “we found something bad” result. The second takeaway is that patients undergoing ABUS can expect fewer short-interval follow-up recommendations. In this cohort, only about 3 percent of ABUS examinations ended in a BI-RADS 3 short-interval follow-up recommendation, compared with nearly 15 percent for HHUS. That means less waiting, fewer repeat visits, and less prolonged uncertainty for many women. Nurses should also discuss modality eligibility. Not every patient is a candidate for ABUS. Women with chest-area implanted devices or piercings, breast implants, prior breast surgery, or sensitivity to the examination lotion may not be able to undergo ABUS. Knowing this in advance helps set realistic expectations. At the same time, nurses should set expectations about biopsy. Because biopsy recommendation rates and false-positive biopsy rates were similar between the two modalities, patients should understand that a biopsy recommendation remains possible with either approach. Having an ultrasound, whether automated or handheld, does not mean a biopsy will never be needed. Finally, nurses can support shared decision-making. Patients who have been notified that they have dense breast tissue may ask about supplemental screening options. Nurses can explain that in this study, ABUS and HHUS showed similar cancer detection rates, while also being honest that this was an observational study and did not measure sensitivity directly. That kind of balanced information helps patients make choices that fit their values and preferences.
In the end, this study offers a more nuanced and hopeful picture of supplemental breast ultrasound. It suggests that automated breast ultrasound can be an effective alternative to handheld ultrasound, with a similar ability to detect cancer and a significantly lower rate of short-interval follow-up recommendations. That is meaningful for patients who are already anxious about dense breasts and worried about the possibility of extra tests. It also highlights the importance of communication. A recall is never a neutral event for a woman; it carries fear, uncertainty, and the weight of waiting. But understanding why a recall happened—and what it does and does not mean—can soften that blow. For oncology nurses, the message is clear: know the difference between BI-RADS 0 and BI-RADS 3, explain it early and often, and help patients navigate the practical and emotional realities of supplemental screening. The study was observational, and more research will be needed to confirm the findings and to understand how ABUS performs in different populations and settings. But for now, there is reason to believe that ABUS offers a path to fewer unnecessary follow-up visits without sacrificing cancer detection. That is a small but meaningful step forward in making breast cancer screening a little less frightening, a little more efficient, and a little more patient-centered. And for the women who receive a callback, the most important thing they need from a nurse is not more statistics, but a calm, clear, and compassionate explanation of what happens next. That kind of support can transform an anxious waiting period into an informed, manageable experience—and that may be the most valuable outcome of all.